Patents by Inventor George Tzertzinis
George Tzertzinis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230022745Abstract: A method of labeling, and optionally enriching, for a population of target RNA molecules in a mixture of RNAs is provided. In some embodiments, the method may comprise (a) adding a label to the 5? end of 5?-diphosphorylated or 5?-triphosphorylated target RNA molecules in a sample by incubating the sample with labeled GTP and a capping enzyme; and (b) optionally enriching for target RNA comprising the affinity tag-labeled GMP using an affinity matrix that binds to the affinity tag. The label may be an oligonucleotide, which may further comprise an affinity group attached either internally or at 5? or 3? end of the oligonucleotide where the oligonucleotide label may be added directly, or indirectly via a reaction with a reactive group to the target RNA.Type: ApplicationFiled: September 14, 2022Publication date: January 26, 2023Applicant: New England Biolabs, Inc.Inventors: Ira Schildkraut, Laurence Ettwiller, Ivan R. Correa, JR., George Tzertzinis, John Buswell, Madalee G. Wulf
-
Patent number: 11479766Abstract: A method of labeling, and optionally enriching, for a population of target RNA molecules in a mixture of RNAs is provided. In some embodiments, the method may comprise (a) adding a label to the 5? end of 5?-diphosphorylated or 5?-triphosphorylated target RNA molecules in a sample by incubating the sample with labeled GTP and a capping enzyme; and (b) optionally enriching for target RNA comprising the affinity tag-labeled GMP using an affinity matrix that binds to the affinity tag. The label may be an oligonucleotide, which may further comprise an affinity group attached either internally or at 5? or 3? end of the oligonucleotide where the oligonucleotide label may be added directly, or indirectly via a reaction with a reactive group to the target RNA.Type: GrantFiled: February 28, 2018Date of Patent: October 25, 2022Assignee: New England Biolabs, Inc.Inventors: Ira Schildkraut, Laurence Ettwiller, Ivan R. Correa, Jr., George Tzertzinis, John Buswell, Madalee G. Wulf
-
Publication number: 20220275352Abstract: A bacteriophage RNA polymerase variant is provided. In some embodiments, the variant may have increased thermostability relative to the corresponding wild type bacteriophage RNA polymerase and/or wild type T7 RNA polymerase. Compositions, kits and methods that employ the variant are also provided.Type: ApplicationFiled: May 11, 2022Publication date: September 1, 2022Applicant: New England Biolabs, Inc.Inventors: Jennifer Ong, Vladimir Potapov, Kuo-Chan Hung, Haruichi Asahara, Shaorong Chong, George Tzertzinis
-
Patent number: 11359184Abstract: A bacteriophage RNA polymerase variant is provided. In some embodiments, the variant may have increased thermostability relative to the corresponding wild type bacteriophage RNA polymerase and/or wild type T7 RNA polymerase. Compositions, kits and methods that employ the variant are also provided.Type: GrantFiled: November 11, 2019Date of Patent: June 14, 2022Assignee: New England Biolabs, Inc.Inventors: Jennifer Ong, Vladimir Potapov, Kuo-Chan Hung, Haruichi Asahara, Shaorong Chong, George Tzertzinis
-
Patent number: 11225658Abstract: Provided herein is a method for making an cDNA library, comprising adding an affinity tag-labeled GMP to the 5? end of targeted RNA species in a sample by optionally decapping followed by incubating the sample with an affinity tag-labeled GTP and a capping enzyme, enriching for RNA comprising the affinity tag-labeled GMP using an affinity matrix that binds to the affinity tag, reverse transcribing the enriched RNA to produce a population of cDNAs, and adding a tail to the 3? end of the population of cDNAs using a terminal transferase, to produce an cDNA library.Type: GrantFiled: October 17, 2017Date of Patent: January 18, 2022Assignee: New England Biolabs, Inc.Inventors: Bo Yan, Laurence Ettwiller, Ira Schildkraut, George Tzertzinis, Ivan R. Correa, Jr., Nan Dai, Madalee G. Wulf
-
Publication number: 20200123513Abstract: A bacteriophage RNA polymerase variant is provided. In some embodiments, the variant may have increased thermostability relative to the corresponding wild type bacteriophage RNA polymerase and/or wild type T7 RNA polymerase. Compositions, kits and methods that employ the variant are also provided.Type: ApplicationFiled: November 11, 2019Publication date: April 23, 2020Applicant: New England Biolabs, Inc.Inventors: Jennifer Ong, Vladimir Potapov, Kuo-Chan Hung, Haruichi Asahara, Shaorong Chong, George Tzertzinis
-
Patent number: 10519431Abstract: A bacteriophage RNA polymerase variant is provided. In some embodiments, the variant may have increased thermostability relative to the corresponding wild type bacteriophage RNA polymerase and/or wild type T7 RNA polymerase. Compositions, kits and methods that employ the variant are also provided.Type: GrantFiled: May 12, 2017Date of Patent: December 31, 2019Assignee: New England Biolabs, Inc.Inventors: Jennifer Ong, Vladimir Potapov, Kuo-Chan Hung, Haruichi Asahara, Shaorong Chong, George Tzertzinis
-
Publication number: 20190024061Abstract: A bacteriophage RNA polymerase variant is provided. In some embodiments, the variant may have increased thermostability relative to the corresponding wild type bacteriophage RNA polymerase and/or wild type T7 RNA polymerase. Compositions, kits and methods that employ the variant are also provided.Type: ApplicationFiled: January 12, 2017Publication date: January 24, 2019Applicant: New England Biolabs, Inc.Inventors: Jennifer Ong, Shaorong Chong, Haruichi Asahara, Kuo-Chan Hung, Vladimir Potapov, George Tzertzinis
-
Publication number: 20180195061Abstract: A method of labeling, and optionally enriching, for a population of target RNA molecules in a mixture of RNAs is provided. In some embodiments, the method may comprise (a) adding a label to the 5? end of 5?-diphosphorylated or 5?-triphosphorylated target RNA molecules in a sample by incubating the sample with labeled GTP and a capping enzyme; and (b) optionally enriching for target RNA comprising the affinity tag-labeled GMP using an affinity matrix that binds to the affinity tag. The label may be an oligonucleotide, which may further comprise an affinity group attached either internally or at 5? or 3? end of the oligonucleotide where the oligonucleotide label may be added directly, or indirectly via a reaction with a reactive group to the target RNA.Type: ApplicationFiled: February 28, 2018Publication date: July 12, 2018Applicant: New England Biolabs, Inc.Inventors: Ira Schildkraut, Laurence Ettwiller, Ivan R. Correa, Jr., George Tzertzinis, John Buswell, Madalee G. Wulf
-
Publication number: 20180030436Abstract: Provided herein is a method for making an cDNA library, comprising adding an affinity tag-labeled GMP to the 5? end of targeted RNA species in a sample by optionally decapping followed by incubating the sample with an affinity tag-labeled GTP and a capping enzyme, enriching for RNA comprising the affinity tag-labeled GMP using an affinity matrix that binds to the affinity tag, reverse transcribing the enriched RNA to produce a population of cDNAs, and adding a tail to the 3? end of the population of cDNAs using a terminal transferase, to produce an cDNA library.Type: ApplicationFiled: October 17, 2017Publication date: February 1, 2018Applicant: New England Biolabs, Inc.Inventors: Bo Yan, Laurence Ettwiller, Ira Schildkraut, George Tzertzinis, Ivan R. Correa, JR., Nan Dai, Madalee G. Wulf
-
Publication number: 20170247670Abstract: A bacteriophage RNA polymerase variant is provided. In some embodiments, the variant may have increased thermostability relative to the corresponding wild type bacteriophage RNA polymerase and/or wild type T7 RNA polymerase. Compositions, kits and methods that employ the variant are also provided.Type: ApplicationFiled: May 12, 2017Publication date: August 31, 2017Applicant: New England Biolabs, Inc.Inventors: Jennifer Ong, Vladimir Potapov, Kuo-Chan Hung, Haruichi Asahara, Shaorong Chong, George Tzertzinis
-
Publication number: 20110060135Abstract: Methods and kits are provided for obtaining small RNAs from a mixture of RNAs of varying sizes such as can be found in a cell lysate or an enzyme-digested RNA. The methods and kits utilize magnetic beads and require the addition of one or more alcohols to bind small RNAs effectively to the beads.Type: ApplicationFiled: November 18, 2008Publication date: March 10, 2011Applicant: NEW ENGLAND BIOLABS, INC.Inventors: George Tzertzinis, Jean-Etienne Morlighem
-
Patent number: 7700758Abstract: A method for obtaining a mixture of heterogenous short double-stranded RNA molecules suitable for use in gene silencing (hsiRNA) by subjecting large double-stranded RNA to enzymatic cleavage under specified conditions. The resulting mixture consistently includes enhanced representation of fragments having a size of 21-22 nucleotides absent any fractionation step. The fragments contain sequences that collectively span the entire length of the large double-stranded RNA from which they are derived. Double-stranded RNA with sequences that individually represent segments of a target mRNA may be analyzed using the methods described herein to identify the most active subset of hsiRNA fragments or individual siRNA fragments for achieving gene silencing for any gene or transcribed sequences. A method is additionally provided for preparing and cloning DNA encoding selected siRNA, hsiRNA mixtures or hairpin sequences to provide a continuous supply of a gene silencing reagent derived from any long double-stranded RNA.Type: GrantFiled: July 18, 2003Date of Patent: April 20, 2010Assignee: New England Biolabs, Inc.Inventors: George Tzertzinis, George Feehery, Christopher Noren, Corinna Tuckey, Larry McReynolds, Yinhua Zhang
-
Patent number: 7695964Abstract: Compositions and methods are provided for preparing an hsiRNA mixture and for silencing of gene expression in vivo. The composition relates to a mutant RnaseIII. The methods are directed to reacting a preparation of dsRNA with an effective amount of a mutant RNAse III to produce the hsiRNA mixture.Type: GrantFiled: January 21, 2005Date of Patent: April 13, 2010Assignee: New England Biolabs, Inc.Inventors: Claude V. Maina, George Tzertzinis, Sanjay Kumar
-
Publication number: 20080206835Abstract: A method for obtaining a mixture of heterogenous short double-stranded RNA molecules suitable for use in gene silencing (hsiRNA) by subjecting large double-stranded RNA to enzymatic cleavage under specified conditions. The resulting mixture consistently includes enhanced representation of fragments having a size of 21-22 nucleotides absent any fractionation step. The fragments contain sequences that collectively span the entire length of the large double-stranded RNA from which they are derived. Double-stranded RNA with sequences that individually represent segments of a target mRNA may be analyzed using the methods described herein to identify the most active subset of hsiRNA fragments or individual siRNA fragments for achieving gene silencing for any gene or transcribed sequences. A method is additionally provided for preparing and cloning DNA encoding selected siRNA, hsiRNA mixtures or hairpin sequences to provide a continuous supply of a gene silencing reagent derived from any long double-stranded RNA.Type: ApplicationFiled: February 11, 2008Publication date: August 28, 2008Applicant: New England Biolabs, Inc.Inventors: George Tzertzinis, George Feehery, Corinna Tuckey, Christopher Noren, Larry McReynolds, Yinhua Zhang
-
Publication number: 20080194028Abstract: Compositions and methods for making the same and uses of the composition are provided where the composition has a plurality of dsRNA fragments with overlapping sequences, each fragment having a size in the range of 18-30 nt, such that the composition is formed by enzymatic digestion of one or more large dsRNAs and less than 2 nM of the composition is capable of specifically silencing expression of a target gene by at least 65% in transfected COS cells.Type: ApplicationFiled: February 14, 2005Publication date: August 14, 2008Applicant: New England Biolabs, Inc.Inventors: George Tzertzinis, Celine Petit, George Feehery
-
Publication number: 20070155684Abstract: Compositions and methods are provided for preparing an hsiRNA mixture and for silencing of gene expression in vivo. The composition relates to a mutant RnaseIII. The methods are directed to reacting a preparation of dsRNA with an effective amount of a mutant RNAse III to produce the hsiRNA mixture.Type: ApplicationFiled: January 21, 2005Publication date: July 5, 2007Applicant: New England Biolabs, Inc.Inventors: Claude Maina, George Tzertzinis, Sanjay Kumar
-
Publication number: 20040038278Abstract: A method for obtaining a mixture of heterogenous short double-stranded RNA molecules suitable for use in gene silencing (hsiRNA) by subjecting large double-stranded RNA to enzymatic cleavage under specified conditions. The resulting mixture consistently includes enhanced representation of fragments having a size of 21-22 nucleotides absent any fractionation step. The fragments contain sequences that collectively span the entire length of the large double-stranded RNA from which they are derived. Double-stranded RNA with sequences that individually represent segments of a target mRNA may be analyzed using the methods described herein to identify the most active subset of hsiRNA fragments or individual siRNA fragments for achieving gene silencing for any gene or transcribed sequences. A method is additionally provided for preparing and cloning DNA encoding selected siRNA, hsiRNA mixtures or hairpin sequences to provide a continuous supply of a gene silencing reagent derived from any long double-stranded RNA.Type: ApplicationFiled: July 18, 2003Publication date: February 26, 2004Inventors: George Tzertzinis, George Feehery, Corinna Tuckey, Christopher Noren, Larry McReynolds